Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation
暂无分享,去创建一个
J. Wagner | G. Vercellotti | M. Verneris | N. Bejanyan | C. Ustun | D. Weisdorf | B. Oran | R. Shanley | C. Brunstein | E. Warlick
[1] P. Armand,et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] D. Blaise,et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia , 2013, Leukemia & lymphoma.
[3] Jeffrey S. Miller,et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] N. Kröger,et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.
[5] K. Dusenbery,et al. Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia , 2011 .
[6] J. Wingard,et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.
[7] D. Kaufman,et al. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] E. Estey,et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] S. Mielke,et al. Management of relapse after allo-SCT for AML and the role of second transplantation , 2009, Bone Marrow Transplantation.
[10] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[11] M. Aker,et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] D. Porter,et al. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.
[13] M. Labopin,et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Wagner,et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. , 2007, Blood.
[15] U. Popat,et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] J. Kell. Treatment of relapsed acute myeloid leukaemia. , 2006, Reviews on recent clinical trials.
[17] Je-Hwan Lee,et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse , 2004, Leukemia.
[18] M. Tallman,et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.
[19] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[20] T. Braun,et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. H. Lee,et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. , 2001, Leukemia research.
[22] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[23] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[24] T. Montgomery. The umbilical cord. , 1960, Clinical obstetrics and gynecology.
[25] เอกรัฐ รัฐฤทธิ์ธำรง. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation , 2009 .
[26] R. Storb,et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.